Association of 20 potential ATP2B1‐interacting genes with blood pressure in Koreans

Kyung‐Won Hong,Hyun‐Seok Jin,Ji‐Eun Lim,Bermseok Oh 한국유전학회 2011 Genes & Genomics Vol.33 No.3

Plasma membrane calcium‐transporting ATPase 1 (ATP2B1)is associated significantly with blood pressure in Caucasians and Asians. ATP2B1 regulates calcium homeostasis and belongs to the P‐type calcium pump family; several studies have identified diverse proteins that bind to ATP2B1. We hypothesized that ATP2B1 regulates blood pressure through ATP2B1‐interacting genes. To this end, 20 potential ATP2B1‐interacting genes were selected, 197 SNPs of which were analyzed for their association of systolic and diastolic blood pressure. These 20 genes were categorized into 2 groups: ATP2B1‐binding genes and ATP2B1‐cleaving calpain family members. Three ATP2B1‐binding genes (CALM1, NOS1, and PDLIM1)were associated with blood pressure, and a SNP in CALM1(rs2401887) generated the strongest association signal (beta=‐3.60±0.92, p=8.9×10^(‐5) for systolic blood pressure and beta=‐1.40±0.62, p=0.02 for diastolic blood pressure). Of the calpain family members, 3 genes (CAPN6, CAPN9, and CAPN10)were associated with blood pressure, and the CAPN10 SNP rs4676348 yielded the strongest association signal (beta=‐0.88±0.27, p=0.001 for systolic blood pressure and beta=‐0.58±0.18, p=0.015 for diastolic blood pressure). Further, the interaction of CALM1 to ATP2B1 was examined using the blood pressure of individuals who carried both variants of CALM1and ATP2B1 genes. Similarly the interaction of CAPN10 to ATP2B1 was also examined. The CALM1 variant (rs2401887)and CAPN10 variants (rs4676348) appear to decrease blood pressure further in addition to the decrease by the variant (rs17249754) of ATP2B1, which suggests that ATP2B1 might regulate blood pressure through the ATP2B1‐interacting genes CALM1 and CAPN10.

진심통(眞心痛)에 관(關)한 문헌적(文獻的) 고찰(考察)

전찬용,조기호,이원철,김영석,배형섭,이경섭,구본홍,Jun, Chan-Yong,Jo, Ki-Ho,Lee, Won-Chol,金永錫, Yong-Seok,Bhae, Hyung-Sup,Lee, Kyung-Sup,Goo, Bon-Hong 대한한방내과학회 1990 大韓韓方內科學會誌 Vol.11 No.1

The true heartache is a condition of severe heartache corresponding to angina pectoris, as recorded from Hwang Jae Nai Kyung. According to the literatural study of true heartache, some results can be acquired, such as follows. 1. The site of the true Heartache, can be divided into two categories, first, its superficial and conscious area is the chest as same as the other heartache. But its inner lesion is the Heart-Meridian as others occupied at the Pericardium-Meridian in stead of the Heart-Meridian. 2. The etiological classification of true heartache, are Cold-evil, Heat-evil, Wind-evil, Blood stasis etc. But its major factor is Cold-evil, more than anything else. 3. The symptomatic signs of true heartache, consist of cyanotic change from hands and feet to phalanges; severe heartache pale complexion with cold breathing and its extreme state can manifestate unceased sweating called as Yang exhaustion.

Molecular Relationship of Hylobates Based on Alu Elements of the Y Chromosome

Kyung Won Hong,Jae Won Huh,Dae Soo Kim,Hong Seok Ha,Heui Soo Kim 한국유전학회 2007 Genes & Genomics Vol.29 No.3

The phylogenetic relationship among the subgenus Hylobates has been debated by morphological and molecular data. We examined such relationship by comparing nucleotide sequences of a Y chromosomal gene, translation initiation factor 1A Y chromosome (EIF1AY), in humans, chimpanzees, gorillas, orangutans and five species of gibbons (white-handed gibbon, agile gibbon, kloss`s gibbon, muller`s gibbon, pileated gibbon) using PCR amplification and sequencing. Among hominoid primates, gibbons alone contained Alu elements in their EIF1AY gene of the Y chromosome. In addition, new diagnostic mutation sites named AluYHy as new Alu member were identified in gibbons. Phylogenetic analysis of AluYHy sequences indicated a sister relationship between H. lar and H. klossii. These suggest that the new AluYHy of Y chromosome can be use for understanding gibbon phylogeny and evolution.

Evaluation of Two Species of Soft Wood Decay Resistance for Heat-Treated Wood Using the Catalyst (H₂SO₄)¹

Kyung-rok Won,Nam-euy Hong,Su-young Jung,Byung-ro Kim,Hee-seop Byeon 한국목재공학회 2017 목재공학 Vol.45 No.2

This study was conducted to evaluate the resistance of heat-treated wood using the catalyst to decay caused by fungi for sapwood and heartwood of two tree species, Korean red pine (Pinus densiflora) and Japanese larch (Larix kaempferi), respectively. Wood samples were immersed for 10 min in sulfuric acid (7.5%) and then heat-treated at 130℃ for 90 min. Fomitopsis palustris, a brown-rot fungus, was used to examine the decay re-sistance of Korean red pine and Japanese larch wood. Weight and density of wood from the all conditions in-creased after heat treatment using the catalyst. Weight loss after decay resistance test was also dropped with a heat treatment. The lowest weight loss indicated at heat-treated heartwood of Japanese larch. Heat treatment us-ing the catalyst effectively increased the resistance of wood to decay caused by fungi.

A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETT

Hong, Soon Jun,Jeong, Han Saem,Ahn, Jeong Cheon,Cha, Dong-Hun,Won, Kyung Heon,Kim, Weon,Cho, Sang Kyoon,Kim, Seok-Yeon,Yoo, Byung-Su,Sung, Ki Chul,Rha, Seung-Woon,Shin, Joon-Han,Han, Kyoo Rok,Chung, W Elsevier 2018 Clinical therapeutics Vol.40 No.2

<P><B>Abstract</B></P> <P><B>Purpose</B></P> <P>Combination therapy with ezetimibe and statins is recommended in cases of statin intolerance or insufficiency. The objective of this study was to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with hypercholesterolemia.</P> <P><B>Methods</B></P> <P>I-ROSETTE (Ildong ROSuvastatin & ezETimibe for hypercholesTElolemia) was an 8-week, double-blind, multicenter, Phase III randomized controlled trial conducted at 20 hospitals in the Republic of Korea. Patients with hypercholesterolemia who required medical treatment according to National Cholesterol Education Program Adult Treatment Panel III guidelines were eligible for participation in the study. Patients were randomly assigned to receive ezetimibe 10 mg/rosuvastatin 20 mg, ezetimibe 10 mg/rosuvastatin 10 mg, ezetimibe 10 mg/rosuvastatin 5 mg, rosuvastatin 20 mg, rosuvastatin 10 mg, or rosuvastatin 5 mg in a 1:1:1:1:1:1 ratio. The primary end point was the difference in the mean percent change from baseline in LDL-C level after 8 weeks of treatment between the ezetimibe/rosuvastatin and rosuvastatin treatment groups. All patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs.</P> <P><B>Findings</B></P> <P>Of 396 patients, 389 with efficacy data were analyzed. Baseline characteristics among 6 groups were similar. After 8 weeks of double-blind treatment, the percent changes in adjusted mean LDL-C levels at week 8 compared with baseline values were –57.0% (2.1%) and –44.4% (2.1%) in the total ezetimibe/rosuvastatin and total rosuvastatin groups, respectively (<I>P</I> < 0.001). The LDL-C–lowering efficacy of each of the ezetimibe/rosuvastatin combinations was superior to that of each of the respective doses of rosuvastatin. The mean percent change in LDL-C level in all ezetimibe/rosuvastatin combination groups was >50%. The number of patients who achieved target LDL-C levels at week 8 was significantly greater in the ezetimibe/rosuvastatin group (180 [92.3%] of 195 patients) than in the rosuvastatin monotherapy group (155 [79.9%] of 194 patients) (<I>P</I> < 0.001). There were no significant differences in the incidence of overall AEs, adverse drug reactions, and serious AEs; laboratory findings, including liver function test results and creatinine kinase levels, were comparable between groups.</P> <P><B>Implications</B></P> <P>Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.</P>

Evaluation of Sapwood and Heartwood Decay Resistance after Immersion-Treatment with Pyroligneous Liquor

Kyung Rok Won,Nam Euy Hong,Han Min Park,Hee Seop Byeon 한국목재공학회 2016 목재공학 Vol.44 No.6

To evaluate the resistance of wood to decay caused by fungi, sapwood and heartwood of red pine (Pinus densiflora) and sapwood and heartwood of larch (Larix kaempferi) were conducted. Wood samples were immersed for 96 h in pyroligneous liquor. Then, the brown-rot fungus, Fomitopsis palustris, was used to examine the decay resistance of red pine and larch. Weight and density of wood from the all conditions increased after immersion treatment. Weight loss after decay resistance test was also dropped with a immersion treatment. The lowest weight loss indicated at immersion-treated heartwood of larch. Immersion treatment using pyroligneous liquor effectively increased the resistance of wood to decay caused by fungi.

Case Report : A Case of Syndrome of Inappropriate Scretion of Anti-Diuretic Hormone Associated with Sodium Valproate

( Hong Joo Lee ),( Jung Kook Wi ),( Ju Young Moon ),( Kyung Hwan Jeong ),( Chun Gyoo Ihm ),( Sang Ho Lee ),( Tae Won Lee ) 대한전해질학회 2012 Electrolytes & Blood Pressure Vol.10 No.1

We report a rare case of the concurrent manifestation of central diabetes insipidus (CDI) and type 2 diabetes mellitus (DM). A 56 year-old man was diagnosed as a type 2 DM on the basis of hyperglycemia with polyuria and polydipsia at a local clinic two months ago and started an oral hypoglycemic medication, but resulted in no symptomatic improvement at all. Upon admission to the university hospital, the patient`s initial fasting blood sugar level was 140mg/dL, and he showed polydipsic and polyuric conditions more than 8 L urine/day. Despite the hyperglycemia controlled with metformin and diet, his symptoms persisted. Further investigations including water deprivation test confirmed the coexisting CDI of unknown origin, and the patient`s symptoms including an intense thirst were markedly improved by desmopressin nasal spray (10 μg/day). The possibility of a common origin of CDI and type 2 DM is raised in a review of the few relevant adult cases in the literature.

Kidney transplantation in human immunodeficiency virus-infected patients: a report of two cases and a review of the literatures

Hong Pil Hwang,Hee Chul Yu,Kyung Pyo Kang,Won Kim,박성광,Jeong Sang Ku,Hyeongwan Kim,Sik Lee 대한이식학회 2019 Korean Journal of Transplantation Vol.33 No.3

Human immunodeficiency virus (HIV) infection was traditionally considered an absolute contraindication for transplantation because of concerns about HIV disease progression due to immunosuppression. Since potent antiretroviral therapies (ARTs) have become widely available, the prognosis of HIV-infected kidney transplant recipients has dramatically improved. Recent results of prospective multicenter trials on kidney transplantation (KT) in HIV-positive candidates have demonstrated the success and challenges of transplantation in this population. Several studies have reported comparable patient and graft outcomes between HIV-infected and HIV-uninfected recipients after KT in the era of potent combined ARTs. We report two cases of HIV-infected patients who underwent KT at our hospital. In this paper, we present a detailed report of two cases and provide a short review of the existing literature.

Synthesis of the C11-C21 Fragments of Epothilones A and B Using Ring-Closing Metathesis

Hong, Yong-Deog,Lee, Hyo-Won,Choi-Lee, Ihl-Young,Jung, Jae-Kyung Korean Chemical Society 2007 Bulletin of the Korean Chemical Society Vol.28 No.3

The Antro-pyloric Capsular Movement by Capsule Endoscopy

( Kyung Min Kim ),( Joon Seong Lee ),( Tae Hee Lee ),( Won Young Cho ),( Hyun Gun Kim ),( Jin Oh Kim ),( Joo Young Cho ),( Su Jin Hong ) 대한소화기기능성질환·운동학회 2010 Journal of Neurogastroenterology and Motility (JNM Vol.16 No.2

Background/Aims: Capsule endoscopy (CE) is used for various purposes. The aims of this study were to classify the types of antro-pyloric capsular movement in CE and to investigate the relationship between the types of capsular movement and clinical factors, including gastric emptying time (GET). Methods: Out of 103 patients who received CE between January 2004 and July 2006, 82 patients (33 female, mean age of 50.6 years) were retrospectively analyzed for capsular movement; 21 patients were excluded because of the history of medications and previous surgeries. CE images were interpreted by a single investigator in relation to the GET and types of antro-pyloric capsular movement. Results: Antro-pyloric capsular movement was classified into four patterns: type 1, Large Longitudinal to-and-fro movements in the antrum followed by passage through the pylorus without resistance; type 2, after Large Longitudinal to-and-fro movements, passage through the pylorus with resistance (> 1 minute); type 3, mixed pattern of type 1 and 4; type 4, weak movement. Median GET by CE were 14.1 minutes (range, 1.2-50.1), 21.7 minutes (6.2-154.9), 57.3 minutes (14.9-249.8), and 58.8 minutes (21.0-249.5) for type 1, 2, 3, and 4, respectively. GET in type 1 and 2 were significantly shorter than that in type 3and 4 (p < 0.05). Ten diabetic patients presented with type 2 (n = 5), 3 (n = 3), and 4 (n = 2) patterns, but not with type 1.Conclusions: Our results suggest the analysis of capsule movement using CE to be a possible method of evaluating the antro-pyloric movement.(J Neurogastroenterol Motil 2010;16:172-176)